IL-6 and IGF-I have been shown to be able to confer MM cells with resistance to therapeutics through induction of phosphatidylinositol 3-kinase (PI3-K)/Akt and/or Janus-activated kinase 2 (Jak2)/signal transducers and activators of transcription 3 (Stat3) signaling [29], [46], [47]. This evidence concerns the gene IGF1 and Miyoshi myopathy.